The first regulatory testing ground for the current generation of gene engineering technology candidates based on chimeric antigen receptors is likely to be acute lymphoblastic leukemia, an indication in which therapies can target an antigen, CD19, that is expressed only on B-cells, limiting the possibility of off-target effects.
Early studies presented at the American Society of Hematology meeting in December spurred excitement about the autologous technology’s potential in...